FDA Moves to Ban Compounded GLP-1 Drugs, Ending $400-Per-Month Alternative to $1,300 Brand Weight-Loss Medications
The FDA plans to ban compounded semaglutide and tirzepatide following supply recovery of Ozempic, Wegovy, and Mounjaro, eliminating the legal basis for low-cost copies. US telehealth firms including TomorrowsRx, Hims & Hers, and Ro built businesses on $200-$400 monthly compounded prescriptions versus $900-$1,300 brand prices. The crackdown threatens revenue models unavailable in most markets where compounding regulations differ.
ViaNews Editorial Team•